Effects of the sGC stimulator BAY 41-2272 are not mediated by phosphodiesterase 5 inhibition

被引：25

作者：

Bischoff, E ^{[1
]}

Stasch, JP ^{[1
]}

机构：

[1] Bayer Healthcare, Cardiovasc Res, Wuppertal, Germany

来源：

CIRCULATION | 2004年 / 110卷 / 12期

关键词：

D O I：

10.1161/01.CIR.0000142209.28862.12

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：E320 / E320

页数：1

共 5 条

[1] Antiplatelet properties of a novel, non-NO-based soluble guanylate cyclase activator, BAY 41-2272 [J].

Hobbs, AJ ;

Moncada, S .

VASCULAR PHARMACOLOGY, 2003, 40 (03) :149-154

[2]

KALSI JS, 2004, INT J IMPOT RES 0318

[3] Inhibition of phosphodiesterase type 5 by the activator of nitric oxide-sensitive guanylyl cyclase BAY 41-2272 [J].

Mullershausen, F ;

Russwurm, M ;

Friebe, A ;

Koesling, D .

CIRCULATION, 2004, 109 (14) :1711-1713

[4] NO-independent regulatory site on soluble guanylate cyclase [J].

Stasch, JP ;

Becker, EM ;

Alonso-Alija, C ;

Apeler, H ;

Dembowsky, K ;

Feurer, A ;

Gerzer, R ;

Minuth, T ;

Perzborn, E ;

Pleiss, U ;

Schröder, H ;

Schroeder, W ;

Stahl, E ;

Steinke, W ;

Straub, A ;

Schramm, M .

NATURE, 2001, 410 (6825) :212-215

[5]

WUNDER F, 2003, BMC M 1 INT C CGMP S, V1, P59

← 1 →